PUBLIC COMPANY
savePLATINUM
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaThe U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…fda_press · 5d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 7d ago
- Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…fiercebiotech · 14d ago
- GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trialA phase 3 trial has linked GSK’s risvutatug rezetecan to a 67% reduction in the risk of disease progression or death, providing evidence that B7-H3-directed antibody-drug conjugates work in relapse…fiercebiotech · 15d ago
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…biospace · 16d ago
- ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancerWhen used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…biospace · 16d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 16d ago
- ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after ‘great result’ in early-stage testZentalis Pharmaceuticals has pointed to the first overall survival (OS) analysis for azenosertib as proof that the oral WEE1 tyrosine kinase inhibitor can offer a convenient oral treatment for a tr…fiercebiotech · 20d ago
- ESMO: Boehringer builds case for late-phase rival to Amgen’s ImdelltraBoehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year.fiercebiotech · 20d ago
- ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP saysAt the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Al…biospace · 20d ago
comments(0)
5-min edit window · permanent after that